Novartis’ Vas Narasimhan, and Eli Lilly’s David Ricks backed the proposals to end rebates paid to pharmacy benefit managers and health insurers that push up the prices of their diabetes medicines.

UK cost-effectiveness agency NICE has said that Eli Lilly ... In the same period, Lilly reported sales of $253 million for Emgality, and Teva made $98 million from Ajovy. Novartis is hoping ...